Pharmaceutical packaging company acquired by Actavis

Pharmaceutical packaging company PharmaPack has recently been acquired by international generic pharmaceuticals company Actavis for an undisclosed amount. Actavis recently bought 100 percent of the shares of the Dutch pharmaceutical packaging company in order to achieve greater flexibility in tender markets and also be able to manufacture, package and pack pharmaceuticals ... Read More...

Generic Atorvastatin delivered to Spain by Actavis’ sales division, Medis

The Iceland based generic pharmaceutical company, Actavis, recently announced that its third-party sales division, Medis, has delivered around 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market. Atorvastatin efficiently regulates the blood cholesterol levels and ... Read More...

Pantoprazole from Actavis launched on patent expiry in Germany, Ireland, Netherlands

Actavis Group, the international generic pharmaceuticals company, launched Pantoprazole tablets in Germany, Ireland, and the Netherlands as the patent expired on 6 May. This is Actavis Group's first own brand launch of this molecule. In Germany and the Netherlands, the product was also launched by Actavis' third party sales division's (Medis') ... Read More...

Actavis reintroduces Oxycodone in the US

Little Falls facility resumes production with FDA approval of critical pain solution Reykjavik, Iceland, 17 April 2009 -- Actavis Group, the international generic pharmaceuticals company, today announced the reintroduction by its subsidiary in the United States of Oxycodone 15 mg and 30 mg tablet products to pharmacies and customers. Oxycodone is ... Read More...

Fluvastatin SR from Actavis first to market in UK, Holland

Actavis Group, the international generic pharmaceuticals company, today announced the launch of Fluvastatin SR in the UK and the Netherlands. Actavis was first to market in both countries. Fluvastatin SR extended release tablets from Actavis are the generic equivalent of Novartis' Luvinsta® SR / Lescol® XL and are available in 80mg ... Read More...

Actavis starts its business in Ireland

Entering the Irish market last week, Actavis plans to create up to 25 new local jobs over the next five years and to launch more than 120 generic drugs in Ireland, with the potential to save millions of euro off the country’s annual health bill. The new roles Actavis will create ... Read More...

Actavis launches Gemcitabine on patent expiry in EU markets

The international generic pharmaceuticals company, Actavis Group, has launched the oncology product Gemcitabine in EU markets, at patent expiry. This launch represents a significant milestone in Actavis’ developing hospital business. The pharmacuetical drug Gemcitabine is the first major oncology product to be made available by Actavis on the date of patent ... Read More...

Clamelle of Actavis awarded in the UK

At the annual SMaRT Awards last week in Birmingham, UK, Actavis were triumphant, winning Best POM to P Switch of the Year Award for Clamelle. The Clamelle training materials were also awarded Highly Commended in the Best Educational Initiative for Pharmacists category. The SmaRT (Sales, Marketing and Retail Training) Awards, sponsored ... Read More...